Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation (NASDAQ: TECH) provides this centralized hub for investors and industry professionals tracking developments in life sciences innovation. Access official press releases, financial disclosures, and strategic updates from the global leader in bioactive reagents and diagnostic solutions.
This resource delivers timely updates on earnings results, product launches, and strategic collaborations critical to understanding the company's position in biotechnology markets. Users will find announcements related to protein analysis advancements, spatial biology innovations, and global distribution partnerships.
All content is sourced directly from Bio-Techne's corporate communications, ensuring accuracy for those monitoring investment opportunities or industry trends. Bookmark this page for efficient access to material developments affecting TECH's market performance and scientific impact.
ScaleReady has awarded a $125,000 G-Rex Grant to Seattle Children's Therapeutics, a division of Seattle Children's Research Institute. The grant will support the integration of advanced technologies into their CAR-T cell platform, which has already utilized G-Rex bioreactors to manufacture cell therapy products for hundreds of clinical trial participants.
As part of the grant, Seattle Children's Therapeutics will explore fully closed G-Rex bioreactors and Bio-Techne's GMP-grade cytokines to optimize manufacturing for future trials. They will also receive early access to G-Rex product development and participate in evaluating new devices, including cell separation technology that isolates T-cells without expensive instrumentation.
This grant is part of ScaleReady's larger $20M initiative to advance cell and gene-modified cell therapy development and manufacturing, with individual grants worth up to $300,000.
Bio-Techne (NASDAQ: TECH) has won another legal case against Miltenyi Biotec in the Cologne Regional Court, Germany, regarding the unauthorized reverse engineering of Bio-Techne's proprietary NKG2C/CD159c antibodies. The court found that Miltenyi's antibodies had 100% identical variable regions to Bio-Techne's R&D Systems branded products.
This victory follows a similar 2023 case where Miltenyi was found to have reverse engineered Bio-Techne's TIGIT and CCR-7 antibodies. The court has awarded Bio-Techne monetary damages for sales of the reverse engineered antibodies, reimbursement of costs for demonstrating copying, and rights to additional information about Miltenyi's unlawful activities. Miltenyi retains the right to appeal the ruling.
Bio-Techne (NASDAQ: TECH) has announced that its President and CEO, Kim Kelderman, will deliver a presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 14, 2025, at 10:30 a.m. PST. Interested parties can access a live webcast of the presentation through Bio-Techne's Investor Relations website's IR Calendar page.
Bio-Techne (NASDAQ: TECH) has announced a strategic co-marketing and co-promotion agreement with Waters to enhance biotherapeutic characterization and development processes. The partnership combines Bio-Techne's MauriceFlex™ System for charge separation with Waters' BioAccord™ LC-MS System for liquid chromatography mass spectrometry.
The collaboration has already yielded joint activities in late 2024, including an application note, webinar, and presentations at major conferences such as CASSS MS, Festival of Biologics, and PEGS EU. Scientists from both companies are currently working on analyzing additional biomolecule classes, with plans to showcase results at upcoming scientific conferences through various formats including application notes and webinars.
ScaleReady, along with Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH), and CellReady, has awarded a G-Rex® Grant to Moonlight Bio to support their CAR T cell therapy development for solid tumors. The grant is part of ScaleReady's $20M initiative to advance cell and gene-modified cell therapy development.
The grant provides Moonlight Bio with access to a commercial CAR T manufacturing platform, funding for IND-enabling studies validation runs, Bio-Techne's ProPak™ and GMP Cytokines, and optional analysis of manufacturing batch records by CellReady. Individual grants are worth up to $300,000.
Moonlight Bio's technology is based on research published in Nature, focusing on enhancing engineered T cell therapies by utilizing mutations from T cell malignancies.
Bio-Techne (NASDAQ: TECH) has announced a new distribution partnership with MedSanTek to expand its product reach across Turkey and Azerbaijan. The agreement enables MedSanTek to distribute Bio-Techne's portfolio of brands including R&D Systems, Novus, Tocris, Protein Simple, Advanced Cell Diagnostics, and Asuragen.
MedSanTek, founded in the late 2000s, is a leading in vitro diagnostics and research products distributor in the region, specializing in molecular biology, immunology, cancer research, and cell therapy. The partnership aims to leverage MedSanTek's local market expertise and distribution network to enhance Bio-Techne's presence in Turkey and Azerbaijan's biotechnology, laboratory, and hospital sectors.
Bio-Techne (NASDAQ: TECH) has launched a new ESR1 mutation monitoring assay through its brand Asuragen. The research-use-only assay includes a qPCR detection kit and an isolation kit for cell-free DNA and exosomal RNA. The technology is designed to detect 11 ESR1 ligand-binding domain mutations with high sensitivity, particularly relevant for hormone receptor-positive (HR+) metastatic breast cancer patients.
The assay combines QuantideX® qPCR ESR1 exoMutation Kit with ExoLution™ Plus cfDNA + exoRNA Isolation Kit, offering enhanced sensitivity through detection of both cell-free DNA and exosomal RNA signals. This advancement is significant as ESR1 mutations appear in up to 40% of HR+ metastatic breast cancer patients following endocrine therapy, indicating treatment resistance.
Bio-Techne (NASDAQ: TECH) has announced its participation in the Citi 2024 Global Healthcare Conference. Kim Kelderman, President and Chief Executive Officer, will deliver a presentation on Wednesday, December 4, 2024, at 3:15 p.m. EST. Interested parties can access a live webcast of the presentation through the IR Calendar page on Bio-Techne's Investor Relations website.
GeminiBio has acquired selected fetal bovine serum (FBS) product rights and inventory from Bio-Techne (NASDAQ: TECH). The acquisition includes manufacturing and global sales rights for Bio-Techne's R&D Systems FBS product brands: Optima, Premium Select, and Premium. Following Bio-Techne's decision to discontinue their FBS products, GeminiBio will ensure continuous product availability starting December 3, 2024. GeminiBio operates two cGMP manufacturing facilities in West Sacramento, CA, dedicated to animal origin and animal origin-free product manufacturing, serving various life science and biotech customers.
Bio-Techne (NASDAQ: TECH) has announced a new distribution partnership with Leader Life Sciences to expand its presence in the Gulf Cooperation Council (GCC) countries. The agreement covers distribution in Bahrain, Oman, Qatar, Saudi Arabia, and United Arab Emirates. Leader Life Sciences will distribute Bio-Techne's comprehensive portfolio, including antibodies, proteins, immunoassay kits, enzymes, and spatial biology tools to biopharma companies, laboratories, hospitals, and universities in the GCC region. Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and employs over 3,100 people worldwide.
FAQ
What is the current stock price of Bio-Techne (TECH)?
What is the market cap of Bio-Techne (TECH)?
